ESR1 mutation detection in FFPE and Plasma DNA of breast cancer patients using Crystal Digital PCR® and Nio™+.
To detect and quantify the most frequent ESR1 mutations in a single test, a highly multiplexed cdPCR assay was developed: the ESR1 12-plex assay. FFPE DNA and Plasma cfDNA samples from breast cancer patients were analysed using this assay on the Nio™+ system and the results were compared to previously obtained cdPCR results from Centre Eugène Marquis.
Download application note PDF
Learn more about what the Nio™+ instrument and Crystal Digital PCR™ can do for your research
Highlights
- The all-in-one Nio™+ and its associated microfluidic consumable, the Ruby Chip, are suitable with dPCR high-order multiplexing approach such as color combination while significantly reducing the hands-on-time to results.
- The ESR1 12-assay, based on a color combination approach, was successfully applied for monitoring 10 ESR1 mutations and 1 AKT1 mutation simultaneously in a single test. This hyper-plexing approach enables fast and robust data analysis using the Nio™+ system: just one threshold per fluorescent channel to be set and the Nio™ Analyzer Advanced Population Editor will identify and quantify all targets.
- This highly multiplexed assay is compatible with clinical samples (plasma & FFPE DNA) and showed a very good result concordance and MAF correlation with a previous cdPCR study performed with sequential lower multiplexed assays.